atai Life Sciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 9:55 A.M. EDT in New York. Additionally, atai will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference through a pre-recorded fireside chat on June 17 at 7:00 A.M. EDT in a virtual format. Both presentations will be available via webcast on the company's investor relations website, with replays available after the events.

News Market Reaction

+0.43%

1 alert

+0.43% News Effect

On the day this news was published, ATAI gained 0.43%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company’s management team is scheduled to participate in the following investor conferences in June:

Jefferies Global Healthcare Conference

• Format: Fireside Chat
• Date and Time: Thursday, June 5 at 9:55 A.M. EDT
• Location: New York
• Webcast link: here

H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

• Format: Pre-recorded Fireside Chat
• Date and Time: Tuesday, June 17 at 7:00 A.M. EDT
• Location: Virtual
• Webcast link: here

The webcasts of the fireside chats will also be available on the Investors section of the atai website under Events. A replay will be available following the live event.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn.

Contact Information
Investor Contact:
IR@atai.com

Media Contact:
PR@atai.com

FAQ

When is ATAI presenting at the Jefferies Global Healthcare Conference 2025?

ATAI will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 9:55 A.M. EDT in New York.

What type of company is ATAI Life Sciences?

ATAI Life Sciences is a clinical-stage biopharmaceutical company focused on developing highly effective mental health treatments to transform patient outcomes.

Where can investors watch ATAI's conference presentations?

Investors can watch the webcasts of both presentations in the Investors section of the atai website under Events, with replays available after the live events.

When is ATAI's presentation at the H.C. Wainwright Neuro Conference 2025?

ATAI will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on Tuesday, June 17, 2025, at 7:00 A.M. EDT in a virtual format.